I agree with you. I don’t agree that it’s a non event unless it’s submission of the US FDA IND. This is significant news as for weeks shareholders were asking about what’s happening in China. We now see the partnership is intact, funds are arriving, and human clinical trials are nearing. This is positive to hear from shareholders. Not every update should be measured about whether a press release is appealing to new investors. However, I think this is as well. They don’t always rush to their E*TRADE or whatever. News soaks in as part of an overall picture.

Good news, Joe. Keep it rolling.